Hemogenyx Pharmaceuticals Plc (HOPHF)
USD 1.24
(0.0%)
USD 1.24
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 6.46 Million GBP | 120.62% |
| 2022 | 2.93 Million GBP | 15.07% |
| 2021 | 2.54 Million GBP | 36.52% |
| 2020 | 1.86 Million GBP | 49.33% |
| 2019 | 1.24 Million GBP | -0.98% |
| 2018 | 1.26 Million GBP | 82.67% |
| 2017 | 690.68 Thousand GBP | 67.65% |
| 2016 | 411.99 Thousand GBP | 133.16% |
| 2015 | 176.7 Thousand GBP | 2718.21% |
| 2014 | 6270.00 GBP | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 1345.57 GBP | 0.0% |
| 2024 Q1 | 1345.57 GBP | 19.63% |
| 2023 Q3 | 1124.82 GBP | -99.97% |
| 2023 FY | 4.91 Million GBP | 67.63% |
| 2023 Q4 | 1124.81 GBP | -0.0% |
| 2023 Q2 | 3.89 Million GBP | 184724.88% |
| 2023 Q1 | 2108.11 GBP | -99.91% |
| 2022 Q1 | 571.62 GBP | -99.96% |
| 2022 FY | 2.93 Million GBP | 15.07% |
| 2022 Q3 | 1427.15 GBP | -99.87% |
| 2022 Q4 | 2.32 Million GBP | 162634.31% |
| 2022 Q2 | 1.11 Million GBP | 194260.96% |
| 2021 Q1 | 495.63 GBP | -99.96% |
| 2021 FY | 2.54 Million GBP | 36.52% |
| 2021 Q4 | 1.47 Million GBP | 107394.67% |
| 2021 Q3 | 1374.11 GBP | -99.88% |
| 2021 Q2 | 1.09 Million GBP | 221704.34% |
| 2020 Q3 | 622.91 GBP | -99.93% |
| 2020 Q2 | 861.03 Thousand GBP | 210080.54% |
| 2020 Q4 | 1.18 Million GBP | 189750.4% |
| 2020 Q1 | 409.66 GBP | -99.95% |
| 2020 FY | 1.86 Million GBP | 49.33% |
| 2019 FY | 1.24 Million GBP | -0.98% |
| 2019 Q4 | 829.8 Thousand GBP | 216385.66% |
| 2019 Q3 | 383.31 GBP | -99.95% |
| 2019 Q2 | 759.59 Thousand GBP | 215576.02% |
| 2019 Q1 | 352.19 GBP | -25.21% |
| 2018 Q3 | 470.90 GBP | 45.15% |
| 2018 Q2 | 324.43 GBP | -0.0% |
| 2018 Q4 | 470.90 GBP | 0.0% |
| 2018 Q1 | 324.43 GBP | -71.41% |
| 2018 FY | 1.26 Million GBP | 82.67% |
| 2017 Q4 | 1134.81 GBP | 0.0% |
| 2017 FY | 690.68 Thousand GBP | 67.65% |
| 2017 Q1 | 65.47 GBP | 0.0% |
| 2017 Q3 | 1134.81 GBP | 1633.24% |
| 2017 Q2 | 65.47 GBP | 0.0% |
| 2016 FY | 411.99 Thousand GBP | 133.16% |
| 2015 FY | 176.7 Thousand GBP | 2718.21% |
| 2014 FY | 6270.00 GBP | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 92.55% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -31.475% |
| SQZ Biotechnologies Company | 85.61 Million USD | 92.448% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 78.121% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 82.645% |
| Mesoblast Limited | 5.9 Million USD | -9.553% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -330.511% |
| Genus plc | 147.7 Million USD | 95.622% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 26.351% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -381.97% |
| Marizyme, Inc. | 19.23 Million USD | 66.393% |
| ContraFect Corporation | 56.88 Million USD | 88.634% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 22.463% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -46.662% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -337.25% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -121.719% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -131.721% |
| MultiCell Technologies, Inc. | 567.42 USD | -1139416.76% |
| Accustem Sciences Inc. | 3.74 Million USD | -72.587% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 92.477% |
| EV Biologics, Inc. | 531.96 Thousand USD | -1115.471% |
| Q BioMed Inc. | 3.43 Million USD | -88.145% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 73.838% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -1559.756% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -146.082% |
| Biomind Labs Inc. | 994.18 Thousand USD | -550.368% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 97.133% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 3.754% |
| Skye Bioscience, Inc. | 13.54 Million USD | 52.273% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -215.606% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 25963.384% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -28.239% |
| IMV Inc. | 37.7 Million USD | 82.853% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 59.614% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -252.344% |
| GB Sciences, Inc. | 1.42 Million USD | -355.178% |
| Alpha Cognition Inc. | 9.7 Million USD | 33.38% |
| HST Global, Inc. | 140.9 Thousand USD | -4488.733% |
| CSL Limited | 3.44 Billion USD | 99.813% |
| Halberd Corporation | 74.84 Thousand USD | -8539.328% |
| Enzolytics Inc. | 2.17 Million USD | -196.666% |
| Resverlogix Corp. | 12.71 Million USD | 49.136% |
| Affymax, Inc. | 39.38 Million USD | 83.583% |
| SYBLEU INC | 160.87 Thousand USD | -3919.149% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -77.112% |
| argenx SE | 1.53 Billion USD | 99.578% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 88.743% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -519.334% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -309.398% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -89.894% |
| AVAX Technologies, Inc. | 7.31 Million USD | 11.551% |
| Zenith Capital Corp. | 8.94 Million USD | 27.699% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.217% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -37015.24% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -163.341% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -3669.975% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 93.491% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -267.445% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | -227.877% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -246.811% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 40.5% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -236.604% |
| BioStem Technologies, Inc. | 22.97 Million USD | 71.857% |
| ONE Bio Corp. | 6.44 Million USD | -0.341% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -3462.744% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -384.177% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -474.788% |
| Agentix Corp. | 1.37 Million USD | -371.355% |
| LadRx Corporation | 3.81 Million USD | -69.628% |
| Cell Source, Inc. | 4.32 Million USD | -49.487% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -1456.239% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -600.138% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -600.138% |
| NovAccess Global Inc. | 2.46 Million USD | -162.119% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -168.858% |
| Itoco Inc. | 919.14 Thousand USD | -603.465% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -52.553% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -477.824% |
| Kadimastem Ltd | 2.41 Million USD | -168.28% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -2370.464% |
| CytoDyn Inc. | 18.05 Million USD | 64.194% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -25589.721% |
| Mobile Lads Corp. | 554.54 Thousand USD | -1065.971% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -2837.979% |
| Qrons Inc. | 643.67 Thousand USD | -904.517% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -355.408% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -189.964% |
| Rebus Holdings, Inc. | 664 Thousand USD | -873.772% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -255.986% |
| International Stem Cell Corporation | 5.27 Million USD | -22.668% |
| Bioxytran, Inc. | 3.82 Million USD | -69.256% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -12182.675% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -31684.132% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 82.171% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -299.62% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -778.709% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -107.838% |
| Neutra Corp. | 243.82 Thousand USD | -2551.882% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 62.961% |
| PureTech Health plc | 144.59 Million USD | 95.528% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 68.444% |
| IXICO plc | 4.7 Million USD | -37.367% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 26.499% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 94.509% |
| CSL Limited | 3.89 Billion USD | 99.834% |
| Cellectis S.A. | 97.32 Million USD | 93.356% |